Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Revenue of Catalyst Pharmaceuticals, Inc. (CPRX)
Revenue in 2023 (TTM): $398.2 M
According to Catalyst Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $398.2 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Catalyst Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $398.2 M | $313.67 M | $86.81 M | $94.51 M | $71.41 M |
| 2022 | $214.2 M | $179.81 M | $101.84 M | $104.72 M | $83.08 M |
| 2021 | $140.83 M | $118.95 M | $52.39 M | $52.67 M | $39.48 M |
| 2020 | $119.07 M | $102.03 M | $41.3 M | $41.89 M | $74.98 M |
| 2019 | $102.31 M | $87.55 M | $31.82 M | $33.41 M | $31.88 M |
| 2018 | $500 K | $-19,419,204 | $-35,257,187 | $-34,003,514 | $-34,003,514 |
| 2017 | $ | $-45,689 | $-18,492,732 | $-18,412,377 | $-18,412,377 |
| 2016 | $ | $-43,406 | $-18,029,048 | $-18,072,452 | $-18,072,452 |
| 2015 | $ | $-34,468 | $-20,463,357 | $-20,232,958 | $-20,232,958 |
| 2014 | $ | $ | $-13,570,988 | $-15,509,061 | $-15,509,061 |
| 2013 | $ | $ | $-8,398,816 | $-12,154,596 | $-12,154,596 |
| 2012 | $ | $ | $-6,350,918 | $-4,076,386 | $-4,076,386 |
| 2011 | $ | $ | $-6,348,227 | $-6,391,062 | $-6,391,062 |
| 2010 | $488.96 K | $488.96 K | $-3,998,440 | $-4,006,323 | $-4,006,323 |
| 2009 | $ | $ | $-7,211,701 | $-7,241,928 | $-7,241,928 |
| 2008 | $ | $ | $-10,531,840 | $-10,564,597 | $-10,564,597 |
| 2007 | $ | $ | $-5,011,368 | $-4,139,493 | $-4,139,493 |
| 2006 | $ | $ | $-2,724,527 | $-2,729,454 | $-2,729,454 |
| 2005 | $ | $ | $-1,820,794 | $-1,805,380 | $-1,805,380 |
| 2004 | $ | $ | $-542,592 | $-539,820 | $-539,820 |
| 2003 | $ | $ | $-428,615 | $ | $-428,615 |
| 2002 | $ | $ | $-255,945 | $-255,945 | $-255,945 |